CA-BIOCYTOGEN
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announced that it has entered into an antibody evaluation and option agreement with Neurocrine Biosciences, Inc. The agreement grants Neurocrine Biosciences access to Biocytogen’s fully human antibodies against multiple specified targets, with an option to license selected antibodies for therapeutic product development, manufacturing and commercialization for all uses worldwide. Additional targets may be included under this agreement subject to mutual agreement. The antibodies were generated by Biocytogen’s proprietary RenMice® platforms.
Under the terms of the agreement, if options are exercised, Biocytogen will be entitled to option-exercise fees, development and commercialization milestone payments, as well as single-digit royalties on net sales for each selected target.
Dr. Yuelei Shen, President and CEO of Biocytogen, said, “We are pleased that our RenMice®-derived fully human antibodies received recognition from Neurocrine Biosciences, a world-leading neuroscience-focused biopharmaceutical company. We are optimistic that the combination of our comprehensive, validated off-the-shelf antibody sequences and Neurocrine’s extensive experience in novel drug development will accelerate the path to help conquer neurological diseases that are difficult to treat.”
“We are excited to evaluate the therapeutic potential of antibodies generated from Biocytogen’s renowned fully human antibody platforms,” said Jude Onyia, Ph.D., Chief Scientific Officer at Neurocrine Biosciences. “We believe this collaboration will help expand our pipeline with antibody-based drugs and ultimately provide patients with improved treatment options.”
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMabTM/RenLite®/RenNano®/RenTCR-mimicTM) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of June 30, 2023, 50 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 42 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMiceTM, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231219983706/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aspect Expands Cloud Workforce Experience and Developer Tools to New Regions and Introduces AI-Powered Forecasting18.11.2025 15:00:00 CET | Press release
New release brings predictive intelligence, regional expansion, and enhanced employee performance tools to contact center operations. Aspect, a leading provider of cloud-based workforce management solutions, today announced its Q4 2025 product release, delivering AI-powered predictive forecasting for call volume, regional expansion into Canada, UK, and Europe, and new employee performance capabilities. The release represents a significant step forward in Aspect's mission to empower workforces with intelligent, modern tools that drive operational efficiency and employee engagement. AI-Driven Forecasting Brings New Precision and Agility to Workforce Planning The enhanced Forecast Dashboard introduces Predictive Forecasting with built-in AI intelligence. This new feature automatically generates four-week call volume forecasts that refresh daily, eliminating manual setup and enabling planners to make faster, more confident scheduling decisions. By analyzing historical data with advanced al
FireMon Expands Zero Trust Microsegmentation Coverage with Illumio, VMware NSX, and Zscaler18.11.2025 15:00:00 CET | Press release
Deep Illumio integration and continued VMware NSX and Zscaler support, security teams can now operationalize Zero Trust at enterprise scale. FireMon, the leading network security and firewall policy management company, today detailed expanded support for Zero Trust microsegmentation across hybrid environments, including a deeper integration with Illumio and continued coverage for VMware NSX and Zscaler. By normalizing, analyzing, and continuously validating segmentation intent across network, virtual, and host enforcement points, FireMon helps security teams operationalize Zero Trust at enterprise scale. “The future isn’t more consoles,” said Jody Brazil, CEO of FireMon. “It’s one policy playbook that proves control efficacy every day and the evidence to back it up.” Organizations using FireMon to unify segmentation and firewall governance report measurable outcomes, including up to a 90% reduction in compliance reporting time through consolidated policy data and faster validation and
Silicon Labs Partners with Rimini Street to Build a Future-Ready SAP Strategy18.11.2025 15:00:00 CET | Press release
Multi-year strategic partnership empowers Silicon Labs to maximize SAP ECC 6.0 value, accelerate transformation and avoid costly upgrades and disruption Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced Silicon Labs has selected Rimini Street as its strategic partner to maximize the value of its SAP ECC 6.0 investment. This collaboration provides the U.S.-based semiconductor manufacturer with long-term SAP maintenance and professional services to accelerate modernization without costly upgrades or business disruption. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118277544/en/ Silicon Labs Partners with Rimini Street to Build a Future-Ready SAP Strategy Partnership Reduces Technical Debt and Accelerates Modernization Sili
Gurobi Releases Version 13.0 with Improved Performance and New Solving Capabilities18.11.2025 15:00:00 CET | Press release
Users can expect faster solves, new nonlinear capabilities, PDHG with GPU acceleration, and Kubernetes autoscaling. Gurobi Optimization, LLC, the leader in decision intelligence technology, is pleased to announce the release of Gurobi 13.0. This latest version represents a significant advancement in Gurobi’s mission to help organizations tackle increasingly complex optimization challenges with greater speed and flexibility. Version 13.0 introduces performance improvements across core model types, new algorithm support for large-scale and nonlinear problems, GPU acceleration, and expanded cloud-native functionality. “Today’s organizations face optimization challenges that are often domain-specific and more complex than ever,” said Dr. Oliver Bastert, CTO, Gurobi Optimization. “With Gurobi 13.0, we’re extending our technology to handle even larger models and more nonlinear problem types—delivering measurable speed-ups and greater flexibility across a wide range of applications.” Enhancem
Core42 “Maximus-384” Cluster Secures Top 20 Ranking on the Global TOP500 Supercomputers List18.11.2025 14:24:00 CET | Press release
Core42, A G42 Company, secures #20 position with its AMD Instinct MI300X GPU cluster in Buffalo, New York.Results announced ahead of Supercomputing 2025.Collaboration between Core42, Broadcom and Arista Networks delivers a top performing and reliable HPC network with fast data transfers and minimal latency. Core42, a G42 company specializing in sovereign cloud and AI infrastructure, announced that itsMaximus-384 supercomputer has been ranked No. 20 globally on the TOP500 List, the industry’s most recognized benchmark for publicly known supercomputing systems. The ranking highlights the performance of the AMD Instinct™ MI300X GPU-based “Maximus” cluster, operated at the company’s facility in Buffalo, New York and released ahead of Supercomputing 2025, the leading global conference for HPC. The TOP500 list tracks performance trends across the global supercomputing systems using the High Performance Linpack benchmark (HPL) benchmark. Securing a top-20 position reflects exceptional enginee
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom